Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Nephrology | Urology | Family Medicine
Disease Category: Prostate Cancer
Location: United States, ND
To demonstrate superiority in the overall survival of patients with progressive prostate cancer.
Patient Inclusion Criteria:
- Confirmed diagnosis of prostate cancer, patients must have surgical or ongoing chemical castration, patients must have disease that has failed one prior docetaxel-based chemotherapy regimen for the treatment of metastatic disease, disease progression
Patient Exclusion Criteria:
- Prior treatment with sunitinib and more than one prior chemotherapy regimen in the metastatic disease treatment setting, chemotherapy within 3 weeks of the date of the first dose.
Dr. Tom Davis, Director of Business Development
Legacy Pharma Research
601 N. 5th St.
Bismarck, ND 58501
Research Center Information: Legacy Pharma Research
If you would like to learn more about participating in this study, please send an email message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these